Targeting BET proteins downregulates miR-33a to promote synergy with PIM inhibitors in CMML.

Christopher T Letson Maria E Balasis Hannah Newman Moritz Binder Alexis Vedder Fumi Kinose Markus Ball Traci Kruer Ariel Quintana Terra L Lasho Christy M Finke Luciana L Almada Jennifer Margaret Grants Guolin Zhang Martin E Fernandez-Zapico Alexandre Gaspar-Maia Jeffrey E Lancet Rami S Komrokji Eric B Haura David A Sallman Gary W Reuther Aly Karsan Uwe Rix Mirinal S Patnaik Eric Padron

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Inhibition of PIM kinases is a potential novel strategy for overcoming BETi persistence in myeloid neoplasms. Our data supports further clinical investigation of this combination.

Keyphrases

cell proliferation
long non coding rna
electronic health record
bone marrow
acute myeloid leukemia
dendritic cells
long noncoding rna
cancer therapy
big data
immune response
data analysis
human health